Homology Medicines, Inc.

Symbol: 0T6G.L

LSE

21.56

USD

Market price today

  • -0.7390

    P/E Ratio

  • -0.0083

    PEG Ratio

  • 283.62M

    MRK Cap

  • 0.00%

    DIV Yield

Homology Medicines, Inc. (0T6G-L) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

2.83%

Operating Profit Margin

6.82%

Net Profit Margin

8.36%

Return on Assets

-0.37%

Return on Equity

-1.04%

Return on Capital Employed

-0.31%

Company general description and statistics

Sector: Healthcare
Industry: Medical - Pharmaceuticals
CEO:Dr. Paul Alloway J.D., Ph.D.
Full-time employees:7
City:Bedford
Address:One Patriots Park
IPO:2018-10-04
CIK:

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

General Outlook

When we look at how much money they make before expenses, they keep 2.827% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 6.819%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 8.364%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.369% return, is a testament to Homology Medicines, Inc.'s adeptness in optimizing resource deployment. Homology Medicines, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.045%. Furthermore, the proficiency of Homology Medicines, Inc. in capital utilization is underscored by a remarkable -0.313% return on capital employed.

Stock Prices

Homology Medicines, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $26.66, while its low point bottomed out at $25.9. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Homology Medicines, Inc.'s stock market.

Liquidity Ratios

Analyzing 0T6G.L liquidity ratios reveals its financial health of the firm. The current ratio of 725.08% gauges short-term asset coverage for liabilities. The quick ratio (714.19%) assesses immediate liquidity, while the cash ratio (339.29%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio725.08%
Quick Ratio714.19%
Cash Ratio339.29%

Profitability Ratios

0T6G.L profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 644.75% underscores its earnings before tax deductions. The effective tax rate stands at -13.98%, revealing its tax efficiency. The net income per EBT, 129.72%, and the EBT per EBIT, 94.55%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 681.93%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin644.75%
Effective Tax Rate-13.98%
Net Income per EBT129.72%
EBT per EBIT94.55%
EBIT per Revenue681.93%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 7.25, it details the span from stock purchase to revenue. The 7 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding714
Days of Payables Outstanding48
Cash Conversion Cycle-48
Payables Turnover7.63
Fixed Asset Turnover-20.78
Asset Turnover-0.04

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -29.86, and free cash flow per share, -22.86, depict cash generation on a per-share basis. The cash per share value, 25.64, showcases liquidity position. Lastly, the operating cash flow sales ratio, 7.12, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-29.86
Free Cash Flow per Share-22.86
Cash per Share25.64
Operating Cash Flow Sales Ratio7.12
Free Cash Flow to Operating Cash Flow Ratio0.77
Cash Flow Coverage Ratio-1.90
Short Term Coverage Ratio-73.01
Capital Expenditure Coverage Ratio-4.27
Dividend Paid and Capex Coverage Ratio-4.27

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 16.58%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.70, we discern the balance between debt and equity financing. The long-term debt to capitalization, 40.37%, and total debt to capitalization, 41.01%, ratios shed light on its capital structure.

cards.indicatorcards.value
Debt Ratio16.58%
Debt Equity Ratio0.70
Long Term Debt to Capitalization40.37%
Total Debt to Capitalization41.01%
Cash Flow to Debt Ratio-1.90
Company Equity Multiplier4.19

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.36, provides a glimpse into top-line earnings distributed across each share. Net income per share, -35.16, reflects the portion of profit attributed to each share. The book value per share, 22.72, represents the net asset value distributed per share, while the tangible book value per share, 22.72, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.36
Net Income Per Share-35.16
Book Value Per Share22.72
Tangible Book Value Per Share22.72
Shareholders Equity Per Share22.72
Interest Debt Per Share15.79
Capex Per Share-0.07

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -63.97%, indicates top-line expansion, while the gross profit growth, -5.09%, reveals profitability trends. EBIT growth, 30.90%, and operating income growth, 30.90%, offer insights into operational profitability progression. The net income growth, -2156.96%, showcases bottom-line expansion, and the EPS growth, -2139.49%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-63.97%
Gross Profit Growth-5.09%
EBIT Growth30.90%
Operating Income Growth30.90%
Net Income Growth-2156.96%
EPS Growth-2139.49%
EPS Diluted Growth-2139.49%
Weighted Average Shares Growth0.76%
Weighted Average Shares Diluted Growth0.76%
Operating Cash Flow Growth15.34%
Free Cash Flow Growth16.08%
5-Year Revenue Growth per Share184.73%
3-Year Revenue Growth per Share-66.04%
10-Year Operating CF Growth per Share-570.92%
5-Year Operating CF Growth per Share-2863.71%
3-Year Operating CF Growth per Share19.02%
10-Year Net Income Growth per Share-730.36%
5-Year Net Income Growth per Share-2564.29%
3-Year Net Income Growth per Share30.32%
10-Year Shareholders Equity Growth per Share267.53%
5-Year Shareholders Equity Growth per Share387.28%
3-Year Shareholders Equity Growth per Share-70.44%
Asset Growth33.99%
Book Value per Share Growth-59.30%
Debt Growth-95.53%
R&D Expense Growth-36.96%
SGA Expenses Growth-13.68%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 581,270,032.4, captures the company's total value, considering both debt and equity. Income quality, 0.85, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 8.54, gauges operational efficiency, while the research and development to revenue, 5363.49%, highlights investment in innovation.

cards.indicatorcards.value
Enterprise Value581,270,032.4
Income Quality0.85
Sales General and Administrative to Revenue8.54
Research and Development to Revenue5363.49%
Capex to Operating Cash Flow0.24%
Capex to Revenue-19.72%
Capex to Depreciation-39.45%
Stock-Based Compensation to Revenue123.62%
Graham Number134.05
Return on Tangible Assets-36.90%
Graham Net Net-46.83
Working Capital72,341,000
Tangible Asset Value72,991,000
Net Current Asset Value-149,214,000
Invested Capital1
Average Payables2,189,000
Days Payables Outstanding2042
ROIC-74.71%
ROE-1.55%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.14, and the price to book ratio, 1.14, reflect the market's valuation relative to the company's book value. The price to sales ratio, -22.88, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -4.19, and price to operating cash flows, -0.87, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.14
Price to Book Ratio1.14
Price to Sales Ratio-22.88
Price Cash Flow Ratio-0.87
Price Earnings to Growth Ratio-0.01
Enterprise Value Multiple-3.82
Price Fair Value1.14
Price to Operating Cash Flow Ratio-0.87
Price to Free Cash Flows Ratio-4.19
Price to Tangible Book Ratio8.48
Enterprise Value to Sales502.83
Enterprise Value Over EBITDA-6.35
EV to Operating Cash Flow-6.04
Earnings Yield-18.24%
Free Cash Flow Yield-15.58%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Homology Medicines, Inc. (0T6G.L) on the LSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.739 in 2024.

What is the ticker symbol of Homology Medicines, Inc. stock?

The ticker symbol of Homology Medicines, Inc. stock is 0T6G.L.

What is company IPO date?

IPO date of Homology Medicines, Inc. is 2018-10-04.

What is company current share price?

Current share price is 21.560 USD.

What is stock market cap today?

The market cap of stock today is 283616324.000.

What is PEG ratio in 2024?

The current -0.008 is -0.008 in 2024.

What is the number of employees in 2024?

In 2024 the company has 7.